170 related articles for article (PubMed ID: 9922933)
1. Therapeutic inhibition of thrombin activities, receptors, and production.
Harker LA
Hematol Oncol Clin North Am; 1998 Dec; 12(6):1211-30. PubMed ID: 9922933
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
4. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
5. New antithrombotic strategies for resistant thrombotic processes.
Harker LA
J Clin Pharmacol; 1994 Jan; 34(1):3-16. PubMed ID: 8132848
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
7. Strategies for inhibiting the effects of thrombin.
Harker LA
Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356
[TBL] [Abstract][Full Text] [Related]
8. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
Lämmle B; Griffin JH
Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
[TBL] [Abstract][Full Text] [Related]
9. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
10. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
11. Direct thrombin inhibitors.
Maffrand JP
Nouv Rev Fr Hematol (1978); 1992; 34(6):405-19. PubMed ID: 1300540
[TBL] [Abstract][Full Text] [Related]
12. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
13. Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Husmann M; Barton M
Expert Opin Investig Drugs; 2007 May; 16(5):563-7. PubMed ID: 17461731
[TBL] [Abstract][Full Text] [Related]
14. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
Yamamoto J; Inoue N; Otsui K; Ishii H; Gorog DA
Thromb Res; 2014 May; 133(5):919-26. PubMed ID: 24613697
[TBL] [Abstract][Full Text] [Related]
15. VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.
Sivaraja M; Clemens DM; Sizikov S; Dash S; Xu C; Rienzo M; Yang B; Ryan M; Chattopadhyay M; Igoudin L; Chang SS; Keutzer S; Zalicki P; Estiarte MA; Shiau TP; Short KM; Williams DC; Datta A; Pozzi N; Di Cera E; Gibson CM; Fox KAA; Kita DB
Thromb Res; 2020 Jun; 190():112-121. PubMed ID: 32339947
[TBL] [Abstract][Full Text] [Related]
16. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1988 May; 85(9):3184-8. PubMed ID: 3362867
[TBL] [Abstract][Full Text] [Related]
17. Thrombin in arterial thrombosis.
Badimon L; Meyer BJ; Badimon JJ
Haemostasis; 1994; 24(2):69-80. PubMed ID: 7959365
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
André P; LaRocca T; Delaney SM; Lin PH; Vincent D; Sinha U; Conley PB; Phillips DR
Circulation; 2003 Nov; 108(21):2697-703. PubMed ID: 14597584
[TBL] [Abstract][Full Text] [Related]
19. Thrombin hypothesis of thrombus generation and vascular lesion formation.
Harker LA; Hanson SR; Runge MS
Am J Cardiol; 1995 Feb; 75(6):12B-17B. PubMed ID: 7863965
[TBL] [Abstract][Full Text] [Related]
20. Direct thrombin inhibitors.
Di Nisio M; Middeldorp S; Büller HR
N Engl J Med; 2005 Sep; 353(10):1028-40. PubMed ID: 16148288
[No Abstract] [Full Text] [Related]
[Next] [New Search]
